Using the Fatigue Severity Scale to inform healthcare decision-making in multiple sclerosis: mapping to three quality-adjusted life-year measures (EQ-5D-3L, SF-6D, MSIS-8D)

• Published in: Health and quality of life outcomes 2019-08, Vol.17 (1), p.136-136, Article 136
• Main Authors: Goodwin, E, Hawton, A, Green, C
• Format: Article
• Language: English
• Subjects: Algorithms; Care and treatment; Cost benefit analysis; Cost effectiveness; Decision making; Fatigue; Health aspects; Health care costs; Health policy; Lifestyles; Medical care quality; Medical economics; Methods; Multiple sclerosis; Outcomes research; Quality of life; Regression analysis; Risk factors
• ISSN: 1477-7525; 1477-7525
• DOI: 10.1186/s12955-019-1205-y

Fatigue has a major influence on the quality of life of people with multiple sclerosis. The Fatigue Severity Scale is a frequently used patient-reported measure of fatigue impact, but does not generate the health state utility values required to inform cost-effectiveness analysis, limiting its applicability within decision-making contexts. The objective of this study was to use statistical mapping methods to convert Fatigue Severity Scale scores to health state utility values from three preference-based measures: the EQ-5D-3L, SF-6D and Multiple Sclerosis Impact Scale-8D. The relationships between the measures were estimated through regression analysis using cohort data from 1056 people with multiple sclerosis in South West England. Estimation errors were assessed and predictive performance of the best models as tested in a separate sample (n = 352). For the EQ-5D and the Multiple Sclerosis Impact Scale-8D, the best performing models used a censored least absolute deviation specification, with Fatigue Severity Scale total score, age and gender as predictors. For the SF-6D, the best performing model used an ordinary least squares specification, with Fatigue Severity Scale total score as the only predictor. Here we present algorithms to convert Fatigue Severity Scales scores to health state utility values based on three preference-based measures. These values may be used to estimate quality-adjusted life-years for use in cost-effectiveness analyses and to consider the health-related quality of life of people with multiple sclerosis, thereby informing health policy decisions.